Jump Financial LLC Increases Stock Position in Immunocore Holdings plc (NASDAQ:IMCR)

Jump Financial LLC grew its stake in Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 57.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 44,900 shares of the company's stock after purchasing an additional 16,345 shares during the period. Jump Financial LLC owned about 0.09% of Immunocore worth $3,068,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in IMCR. Braidwell LP raised its position in Immunocore by 93.8% during the third quarter. Braidwell LP now owns 906,973 shares of the company's stock worth $47,072,000 after acquiring an additional 438,946 shares during the period. Wellington Management Group LLP lifted its stake in Immunocore by 5.9% in the 3rd quarter. Wellington Management Group LLP now owns 3,913,410 shares of the company's stock valued at $203,106,000 after buying an additional 217,920 shares in the last quarter. Polar Capital Holdings Plc boosted its holdings in Immunocore by 490.5% in the 3rd quarter. Polar Capital Holdings Plc now owns 250,000 shares of the company's stock worth $12,975,000 after buying an additional 207,664 shares during the last quarter. Fiera Capital Corp raised its holdings in shares of Immunocore by 30.4% during the third quarter. Fiera Capital Corp now owns 679,799 shares of the company's stock valued at $35,282,000 after acquiring an additional 158,502 shares during the last quarter. Finally, TD Asset Management Inc lifted its position in shares of Immunocore by 109.9% in the third quarter. TD Asset Management Inc now owns 301,920 shares of the company's stock valued at $15,670,000 after acquiring an additional 158,086 shares in the last quarter. 84.50% of the stock is currently owned by institutional investors and hedge funds.

Immunocore Price Performance

NASDAQ:IMCR traded down $0.90 during mid-day trading on Friday, hitting $58.95. 335,562 shares of the company's stock traded hands, compared to its average volume of 438,995. The firm's 50 day simple moving average is $60.44 and its 200 day simple moving average is $61.63. Immunocore Holdings plc has a 1 year low of $42.21 and a 1 year high of $76.98. The company has a market cap of $2.94 billion, a PE ratio of -48.32 and a beta of 0.92. The company has a debt-to-equity ratio of 1.22, a quick ratio of 3.77 and a current ratio of 5.96.

Immunocore (NASDAQ:IMCR - Get Free Report) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.12). The firm had revenue of $70.30 million for the quarter, compared to analyst estimates of $70.72 million. Immunocore had a negative return on equity of 16.54% and a negative net margin of 22.60%. The business's revenue was up 27.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.35) earnings per share. Sell-side analysts expect that Immunocore Holdings plc will post -1.77 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on IMCR. Guggenheim restated a "buy" rating and issued a $92.00 target price on shares of Immunocore in a report on Tuesday, April 23rd. Canaccord Genuity Group boosted their target price on shares of Immunocore from $63.00 to $67.00 and gave the company a "hold" rating in a report on Thursday. SVB Leerink assumed coverage on shares of Immunocore in a research report on Monday, April 29th. They set an "outperform" rating and a $74.00 price target on the stock. Leerink Partnrs reissued an "outperform" rating on shares of Immunocore in a research note on Monday, April 29th. Finally, HC Wainwright upped their price target on Immunocore from $90.00 to $100.00 and gave the company a "buy" rating in a research note on Thursday. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat.com, Immunocore presently has a consensus rating of "Moderate Buy" and a consensus price target of $82.00.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.